GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » StageZero Life Sciences Ltd (OTCPK:SZLSF) » Definitions » EV-to-FCF

SZLSF (StageZero Life Sciences) EV-to-FCF : -56.82 (As of Mar. 25, 2025)


View and export this data going back to . Start your Free Trial

What is StageZero Life Sciences EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, StageZero Life Sciences's Enterprise Value is $8.30 Mil. StageZero Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.15 Mil. Therefore, StageZero Life Sciences's EV-to-FCF for today is -56.82.

The historical rank and industry rank for StageZero Life Sciences's EV-to-FCF or its related term are showing as below:

SZLSF' s EV-to-FCF Range Over the Past 10 Years
Min: -76.65   Med: -4.47   Max: -0.7
Current: -37.11

During the past 13 years, the highest EV-to-FCF of StageZero Life Sciences was -0.70. The lowest was -76.65. And the median was -4.47.

SZLSF's EV-to-FCF is ranked worse than
100% of 103 companies
in the Medical Diagnostics & Research industry
Industry Median: 27.22 vs SZLSF: -37.11

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-25), StageZero Life Sciences's stock price is $0.05. StageZero Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.011. Therefore, StageZero Life Sciences's PE Ratio (TTM) for today is At Loss.


StageZero Life Sciences EV-to-FCF Historical Data

The historical data trend for StageZero Life Sciences's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StageZero Life Sciences EV-to-FCF Chart

StageZero Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.28 -2.52 -10.37 -2.26 -1.83

StageZero Life Sciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.22 -7.63 -164.70 -52.80 -39.45

Competitive Comparison of StageZero Life Sciences's EV-to-FCF

For the Diagnostics & Research subindustry, StageZero Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


StageZero Life Sciences's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where StageZero Life Sciences's EV-to-FCF falls into.



StageZero Life Sciences EV-to-FCF Calculation

StageZero Life Sciences's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=8.295/-0.146
=-56.82

StageZero Life Sciences's current Enterprise Value is $8.30 Mil.
StageZero Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


StageZero Life Sciences  (OTCPK:SZLSF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

StageZero Life Sciences's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.05/-0.011
=At Loss

StageZero Life Sciences's share price for today is $0.05.
StageZero Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.011.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


StageZero Life Sciences EV-to-FCF Related Terms

Thank you for viewing the detailed overview of StageZero Life Sciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


StageZero Life Sciences Business Description

Traded in Other Exchanges
N/A
Address
70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.